The Investigation of a Patient with an Unusual Coagulation Defect

Summary

1. The coagulation defect of a patient whose blood contains an inhibitor is described.

2. The inhibitor lengthens the clotting time of plasma in the presence of weak thromboplastin and also interferes with the mechanism of glass contact activation.

3. It is suggested that the inhibitor is similar to those which occur in the blood of patients with disseminated lupus erythematosus.

• References

• (1) Bachmann F, Duckert F, Koller F. The Stuart-Prower factor assay and its clinical significance. Thromb. Diath. haem. 2: 24 1958;
• (2) Biggs R, Macfarlane R. G. Human Blood Coagulation and Its Disorders. 2nd ed.. Blackwell Scientific Publications; Oxford: 1957
• (3) Biggs R, Nossel H. L. Tissue extract and the contact reaction in blood coagulation. Thromb. Diath. haem.. 6. 1961
• (4) Koller F, Loeliger A, Duckert F. Le Facteur VII. Rev. Hernat. 7: 156 1952;
• (5) Larrieu M. J, Weilland C. Utilisation de la „céphaline” dans les tests de coagulation. Rev. Hémat. 12: 199 1957;
• (6) Margolis J. Initiation of blood coagulation by glass and related surfaces. J. Physiol. 137: 95 1957;
• (7) Medal L. S, Lisker R. Circulating anticoagulants in disseminated lupus erythematosus. Brit. J. Haemat. 5: 284 1959;
• (8) Soulier J. P. La consommation de la prothrombine pendant la coagulation du sang veineux et du sang capillaire. Rev. Hémat. 3: 302 1948;